Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
05:28am, Monday, 04'th Nov 2024
Regeneron shares fell 9.2% after the Q3 2024 report, making the company's valuation more attractive. The strong report was the 15th of 16 in the last four years to beat expectations. Investors were sp
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
03:44pm, Friday, 01'st Nov 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investo
Regeneron: Investors In Panic Mode On Increased Eylea Fears
06:07am, Friday, 01'st Nov 2024
Shares of Regeneron are in free fall after recent litigation setbacks on Eylea and with Amgen launching a biosimilar low-dose version of Eylea. Investors may be overestimating the negative impact of t
HRMY vs. REGN: Which Stock Is the Better Value Option?
12:41pm, Thursday, 31'st Oct 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two s
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
12:32pm, Thursday, 31'st Oct 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board C
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 31'st Oct 2024
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street es
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
10:15am, Thursday, 31'st Oct 2024
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
08:46am, Thursday, 31'st Oct 2024
Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago.
Regeneron beats results estimates on demand for eczema treatment, eye drug
07:28am, Thursday, 31'st Oct 2024
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye dise
Regeneron Reports Third Quarter 2024 Financial and Operating Results
06:30am, Thursday, 31'st Oct 2024
TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update.
Regeneron to Report Q3 Earnings: What's in the Offing?
03:01pm, Monday, 28'th Oct 2024
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Top Stocks To Buy Now? 2 Biotech Stocks To Watch
11:15am, Monday, 28'th Oct 2024
Biotech stocks to keep an eye on in the stock market right now.
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
10:21am, Monday, 28'th Oct 2024
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
04:20am, Monday, 28'th Oct 2024
One of these players has split its stock in the past. The other one hasn't.
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
11:05am, Thursday, 24'th Oct 2024
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
